
Pfizer saw a 2% drop in sales for the second quarter but has pointed to the stellar growth of its …

Pfizer saw a drop in revenue for the third quarter but the future looks bright as new products begin to …

Two separate Phase III trials of Lyrica have failed to show benefits in treating nerve pain – one in HIV …

Strong sales of Lyrica and its Prevnar vaccines coupled with favourable exchange rates have helped Pfizer deliver a strong quarter. …
Pfizer has again slimmed down its product pipeline as the US giant looks to cut R&D spending and sharpen its …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

